What If Epic Builds It? Handling the Incumbent Objection
Epic building your feature is a real risk, but it's the wrong question to spend your pitch answering. The question that actually predicts whether you survive is whether you can build a position Epic — or any dominant EHR vendor — can't cheaply copy even if it tries: a workflow, a data relationship, or a segment its own incentives make it slow to chase. That's a moat question, not a roadmap question.
Quick Answer: Nobody outside Epic knows what Epic will build next, and a pitch that claims otherwise is guessing. What you can know is the pattern: dominant EHR vendors move slowly on niche, off-core-workflow features because the economics rarely reward the effort, and startups that survive pick problems specific enough that a fast follow doesn't erase their advantage. Build for that pattern, not for a prediction about one company's roadmap.
You'll hear the objection in some form at almost every healthtech pitch meeting: "What happens when Epic just builds this into the chart?" It's a fair question to ask and a lazy one to answer with bravado. The honest response isn't "Epic will never do that" — you have no way to know that, and neither does the person asking. The honest response is an argument about moats: why the feature itself was never the business, and what stays yours even in a world where a much bigger company ships something that looks similar.
The Strongest Version of the Epic Objection: Why Incumbents Do Win Sometimes
The objection is strongest when your product is a thin layer sitting directly on top of data and workflow the incumbent already owns. If a health system's clinicians already live inside the chart all day, and your value proposition is "a better version of something the chart could technically already do," the incumbent doesn't need to out-build you — it only needs to ship a serviceable version and let its existing distribution do the rest.
Three structural advantages make that version of the objection real, and none of them require knowing anyone's roadmap:
- Distribution that's already installed. Epic doesn't need a sales cycle to reach a hospital that already runs Epic. A feature shipped into an existing module reaches every credentialed user the next time the system updates, with no procurement process, no security review, and no new vendor contract for the buyer to approve.
- Switching costs that already favor the incumbent. In Hamilton Helmer's 7 Powers framework, switching costs are one of the most durable barriers a business can hold, and EHR contracts are close to the purest example in software: multi-year terms, deep clinical workflow integration, and a hospital IT org that treats "replace the EHR" as a multi-year, multi-million-dollar project it would rather never repeat. That same switching cost protects whatever the incumbent bundles in.
- A trust relationship you don't have yet. Hospital IT, compliance, and clinical leadership already know how to procure from, audit, and escalate to the vendor running their system of record. A startup asking for a new login, a new integration, and a new vendor risk review is asking for effort a bundled feature never requires.
If your entire pitch is a feature that lives comfortably inside those three advantages, take the objection seriously. That's the scenario where a founder should genuinely worry — not because Epic is guaranteed to build it, but because if it did, your reason to exist would already be thin.
Where Focused Startups Have Held Ground Next to EHR Platforms
Even so, entire categories of healthtech companies have built durable, independent businesses for years in spaces where a large EHR platform offers some version of the same workflow. Patient scheduling and access, clinician-to-clinician communication, telehealth visit delivery, ambient clinical documentation, and prior-authorization or revenue-cycle tooling have all sustained standalone vendors well past the point where a skeptic could have said "the EHR will just add that." These are illustrative examples of a pattern, not a scoreboard of who beat whom — treat them as a starting point for checking your own category, not as proof that any specific company's position is permanent.
The pattern holds for structural reasons that have nothing to do with any single vendor's intentions:
- Certification and regulatory review add friction to anything touching certified functionality. A feature that has to pass through ONC health IT certification pathways or a similar compliance review doesn't ship at startup speed inside a large platform, even when the engineering work itself is straightforward.
- Hospital IT change-control slows adoption regardless of ship date. Most health systems batch EHR upgrades into scheduled release windows — often quarterly or less frequent — so a feature that ships doesn't reach a working clinician for months, and often only after a local configuration and training cycle the health system controls, not the vendor.
- The revenue math doesn't reward niche depth. A platform selling a system-of-record contract priced per bed or per provider has already closed the deal that pays its sales organization. A narrow, workflow-specific improvement rarely moves that number, so it competes for engineering priority against work that does — core stability, interoperability mandates, and the features every customer segment needs, not just one.
- Generalized platforms trade away workflow depth on purpose. A feature built to work across thousands of differently configured health systems has to be generic enough to fit all of them. A specialist solving one workflow for one segment can go deeper than a platform team ever will, because depth for everyone is a different design problem than depth for one persona.
None of this is a guarantee about what any specific company does next — it's a description of why "the incumbent could build it" and "the incumbent will prioritize it, ship it well, and get it adopted quickly" are two very different claims. Conflating them is the actual mistake behind the fear, not the fear itself.
Incumbent Advantages vs. Startup Advantages, by Product Type
Not every corner of healthtech carries the same risk. The table below compares where the structural advantage typically sits by product type — useful for sanity-checking which category your idea actually falls into before you build your moat argument around it.
| Product type | Where the incumbent's advantage is real | Where a focused startup can still win |
|---|---|---|
| Core clinical documentation / chart | Owns the system of record, the login, and the workflow habit | Rarely — this is the incumbent's home turf |
| Scheduling and patient access | Built-in patient portal reaches every existing patient | Deeper self-service logic, multi-location or multi-specialty routing |
| Clinician-to-clinician communication | Native messaging ships with no new login | Cross-organization and cross-EHR reach the native tool can't offer |
| Ambient documentation / AI scribing | Direct chart integration, no separate app to open | Specialty-specific accuracy and workflow tuning a generalist tool skips |
| Prior authorization / revenue cycle | Owns the claims and billing data already in the record | Payer-specific rules engines and appeal workflows built for volume |
| Point-of-care decision support | Embedded in the order-entry workflow already | Evidence depth and specialty focus a horizontal platform won't maintain |
| Cross-system interoperability | None — this by definition means data leaving its walls | Structurally advantaged: the incumbent has no incentive to build this well |
Read the table as a filter, not a verdict: the closer your product sits to the top rows, the more your pitch needs a real answer to the incumbent objection. The closer it sits to the bottom, especially anything that requires moving data across EHR systems rather than deeper into one, the weaker the objection gets — a platform vendor has structurally limited incentive to build a great tool for talking to its competitors' systems.
What This Means for Your Validation Plan
Before you build, name the specific power your business will run on — not the feature, the power. Peter Thiel's Zero to One makes the case that a defensible business needs to be meaningfully better, not marginally better, at the thing that matters to the customer: his rule of thumb is roughly ten times improvement on a dimension people already care about, not ten percent. "We do the same thing as the EHR module, just nicer" fails that test on day one, incumbent or not.
Run these checks as part of your validation work, not after you've already built:
- Does your advantage compound with usage, or does it stay flat? A workflow tool that gets better as more of a customer's specific data flows through it — because you're tuning to their patient population, their payer mix, their specialty — builds a moat that widens over time. A tool that's equally good on day one and year three is a feature, not a business.
- Is your target segment one an EHR-scale platform is structurally likely to deprioritize? Small and rural health systems, single-specialty practices, and workflows that live outside the core chart are frequently underserved not because incumbents can't reach them, but because the revenue per customer doesn't justify bespoke engineering at platform scale.
- Would your product still matter if the incumbent shipped a "good enough" version? Thiel's related idea of a last-mover advantage — being the company still standing and still improving years after the initial land grab, rather than the first company into a space — only works if you're accumulating something durable in the meantime: a data asset, a trained user base, integration depth. If a bundled competing feature would genuinely end your business overnight, that's information to act on now, not a risk to argue away in a pitch deck.
- Have you actually mapped the incumbent's real behavior, not just its logo? Before you build a moat argument, run a real competitor analysis for your digital health startup — what the EHR bundles today, what health systems actually use versus what ships, and where clinicians route around the native tool anyway. That evidence is worth more than any hypothetical about what might ship next quarter.
This work belongs inside your broader validation process, not as a side exercise you do once and file away. If you haven't structured that process yet, start with a full pass on how to validate a healthtech startup idea so the incumbent question gets tested alongside problem severity, willingness to pay, and regulatory fit — not in isolation. And because the Epic question is really one instance of a bigger competitive-mapping problem, the complete competitor analysis playbook walks through building the full picture — direct rivals, indirect workarounds, and incumbent bundling risk together — so your moat argument rests on a real map instead of a gut feeling about one company.
Key Takeaways
- "They could build it" and "they will prioritize, ship, and get it adopted quickly" are different claims. Nobody outside Epic knows its roadmap — treat any pitch or objection that asserts otherwise as speculation, not evidence.
- The objection is strongest against thin, chart-adjacent features. If your product is a nicer layer on data and workflow the incumbent already owns, its existing distribution and switching costs work against you by default.
- Structural friction, not goodwill, is why incumbents move slowly on niche features. Certification review, staged hospital upgrade cycles, and revenue math that rewards core-platform work over narrow depth all apply regardless of any single vendor's intentions.
- Cross-system interoperability is structurally the safest ground. A platform vendor has limited incentive to build a great tool for moving data to its competitors, which is exactly the kind of gap a focused startup can own.
- Aim for ten times better on a dimension that compounds, not a marginally nicer feature. Zero to One's standard and 7 Powers' switching-cost and cornered-resource concepts both point the same direction: build something that gets more valuable with use, not something equally replaceable on day one and year three.
- Map the incumbent for real before you argue about it. A documented competitor analysis beats a hypothetical about what might ship next quarter — and it's evidence you can actually put in front of an investor.
Frequently Asked Questions
Can a startup really compete with Epic?
Yes, in specific ways — not head-on for the core chart, but in categories where Epic's structural incentives make it slow to go deep: cross-system interoperability, single-specialty workflows, and small or rural health systems that don't justify bespoke platform engineering. Startups that pick fights on Epic's home turf, the system of record itself, are the ones that struggle.
What if Epic copies my feature after I launch?
Then the feature was never your moat — the workflow depth, data relationship, or segment focus behind it is. If a copied version would end your business overnight, that's a sign to strengthen what compounds with usage now, before you scale, rather than treating it as a risk to argue away later.
Should I avoid building anything Epic could theoretically build?
No — almost anything is theoretically buildable by a large enough company with enough engineers. The useful question isn't whether it's buildable, it's whether the incumbent has a structural reason to prioritize, ship, and drive adoption of it quickly. Most niche workflow improvements don't clear that bar even when they'd be technically simple to build.
How do I know if my healthtech idea is "Epic-proof"?
No idea is fully incumbent-proof, but you can pressure-test it: check whether your advantage compounds with usage, whether your segment is one large platforms structurally underserve, and whether a "good enough" bundled version would actually end your business. Run the analysis with real data through a full competitor analysis for your digital health startup rather than guessing from a pitch deck.